Federal Judge Accepts Drug Company Filings in 340B Patient Definition Case

Genesis
Genesis Health Care successfully challenged HRSA's 340B patient definition in the U.S. District Court for the District of South Carolina.
A federal district judge has allowed five major drugmakers to file friend-of-the-court briefs in a lawsuit over patient eligibility to [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Health Center Leaders Urge Boards to Push State, Federal Support of 340B

CHI Expo
The National Association of Community Health Centers’ CHI and Expo addressed the advocacy role of health center boards of directors.
The boards of directors of health centers need to take on a bigger advocacy role in support of the 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Health Center Asks Court to Reject Drug Maker Briefs in Challenge to 340B Patient Definition

Genesis
Genesis Health Care successfully challenged HRSA's 340B patient definition in the U.S. District Court for the District of South Carolina.
A health center challenging the government’s 340B program patient definition in a federal district court recently asked a federal judge [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

AHA Urges Dropping Bill Language to Exclude Generic Injectables from 340B

American Hospital Association logo
AHA officials penned a Medical Economics op-ed on “the truth behind growth of the 340B prescription drug program.”
The nation’s largest hospital advocacy organization urged legislators to drop a provision from draft legislation that would exclude generic injectables [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Provider-PhRMA Coalition Adds Civil Rights Group

ASAP 340B
ASAP 340B, a coalition of a drug industry trade group and a community health center organization, added a civil rights group to its membership.
An alliance led by a powerful drug industry trade group and community health center organization that is pushing for 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Drug Maker Owes 340B Providers Repayment, HRSA Pending Audit Finds

Nephron Pharmaceuticals
A HRSA fiscal year 2023 audit tentatively found that drug maker Nephron Pharmaceuticals owes 340B repayments to providers.
The first posted fiscal year 2023 audit of a drug maker tentatively found the company owes repayments to providers. The [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Drugs Among Those at Tornado-Hit Facility Requiring Direct Purchase

Pfizer headquarters
Pfizer has limited multiple 340B-eligible drugs to direct purchase after a tornado damaged one of the drug maker's manufacturing facilities.
Federal officials confirmed that 340B-eligible drugs are among the 12 medications pharmaceutical manufacturer Pfizer has limited to direct purchase after [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Three Terminations, 10 Paybacks to Manufacturers in HRSA’s 2023 Pending Provider Audits

HRSA provider audits
HRSA audits found terminations were required for a 340B provider site and a contract pharmacy and that another provider owed repayments to drugmakers.
Three provider organizations may have contract pharmacies terminated from the 340B program and 10 providers would owe repayments to drug [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Share of Retail Pharmacies that Contract with ‘Core’ 340B Safety-Net Facilities Fell Over Time, Study Finds

JAMA contract pharmacy study
There has been a decline in the share of retail pharmacies that contract with 340B "core safety-net facilities," according to a JAMA Health Forum study.
The proportion of retail contract pharmacies in the 340B program that contract exclusively with “core safety-net” facilities fell from 95% [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Pfizer Changes Costly Cardiac Drugs’ Access Rules for 340B Providers

Pfizer headquarters
Pfizer has limited multiple 340B-eligible drugs to direct purchase after a tornado damaged one of the drug maker's manufacturing facilities.
Drug manufacturer Pfizer is changing how healthcare providers access 340B pricing on two expensive, related heart medicines, effective Nov. 1, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live